echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CDE Yang Zhimin, Xie Songmei: Drug review promotes the development of pediatric drugs through multiple channels, and product reviews are gradually increasing!

    CDE Yang Zhimin, Xie Songmei: Drug review promotes the development of pediatric drugs through multiple channels, and product reviews are gradually increasing!

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The issue of child medication is a livelihood issue that the party and the state attach great importance to, and General Secretary Xi Jinping has issued important instructions on this issue many times


    During the interview, the reporter learned that the drug risporan oral solution for the treatment of rare diseases was launched in the first half of 2021 and was approved for the treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older


    She said: “Through early communication in clinical research and development, we recommend that the original research company conduct clinical trials in China as soon as possible to provide data support for scientific decision-making in drug review


    Publish a list of encouraged R&D


    Yang Zhimin, director of the Department of Clinical Medicine of the Center for Drug Appraisal, pointed out: "To promote the solution of children's drug use problems, regulatory agencies, clinical institutions and drug manufacturers need to work together in the same direction


    In recent years, with the support of major national science and technology projects, a number of children's medical institutions in China have established a relatively complete research and development technology platform for children's drugs, which provides a strong guarantee for the innovative research and development of children's drugs in China


    "The review of children-first and urgently-needed varieties has its own particularities.


    In order to improve the efficiency of variety review, minimize review time, and accelerate the launch of children's drugs, the Center for Drug Evaluation has also set up a special label for "Children's Drugs", which will be connected by a project manager to supervise the review progress and ensure progress in time


    Data shows that among the three batches of clinically urgently needed overseas new drug catalogues released by the National Health and Construction Commission, 16 new drugs that are urgently needed for clinical use in children have been approved for marketing


       As of June 30, 2021, 14 varieties on the list have completed technical review and been approved for marketing, 9 varieties on the list are under review for marketing applications, and 5 varieties on the list have been approved for clinical trials


    Improve the review standard system

      


      The formulation of technical guidelines is an important supervision method for regulating drug research and development and improving the quality and efficiency of drug research


      It is understood that before 2020, the Center for Drug Evaluation only issued three specific guidelines for children's medication


      This year, the Center for Drug Evaluation also published the "Technical Guidelines for the Clinical Trials of Modified New Drugs for Children's Chemicals", "Technical Guidelines for the Writing of Children's Drug-related Information in the Instructions for Chemicals and Biological Products for Treatment", and "Clinical Trials of Attention Deficit Hyperactivity Disorder Drugs" A total of 4 technical guidelines are included in the annual plan


      In addition, in order to standardize the standardization and supplementation of children's drug information in the labeling of listed drugs, the drug review center makes full use of the data resources of children's medical institutions, adopts real-world research methods, follows review technical standards, organizes expert demonstrations, and publicly solicits opinions.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.